<DOC>
	<DOCNO>NCT01009840</DOCNO>
	<brief_summary>Study outcome safety individualize busulfan dose bortezomib patient prepare second stem cell transplant treat multiple myeloma .</brief_summary>
	<brief_title>IV Busulfan Plus Bortezomib Conditioning Regimen Second Autologous Stem Cell Transplant Multiple Myeloma Patients</brief_title>
	<detailed_description>Evaluation six-month response relapse multiple myeloma subject , prior autologous HSCT ( great one year previously ) receive IV busulfan-based conditioning regimen combination pharmacokinetic ( PK ) -guided IV busulfan dose bortezomib , follow second autologous HSCT . Assessment safety profile condition regimen also complete .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1 . Age 18 75 year , inclusive . 2 . Subjects must multiple myeloma require treatment relapsed disease eligible plan autologous HSCT . 3 . Subjects must one previous autologous HSCT , least one year prior plan autologous HSCT study . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 . 5 . Negative betahuman chorionic gonadotropin ( βHCG ) pregnancy test woman childbearing potential . 6 . Subjects surgically sterile ( ie , undergone orchidectomy hysterectomy ) ; female subject postmenopausal least 12 consecutive month ; subject agree remain abstinent practice doublebarrier form birth control trial screen 30 day ( female ) 90 day ( male ) last dose investigational medicinal product ( IMP ) . If employing birth control , two follow precaution must use : vasectomy , tubal ligation , vaginal diaphragm , intrauterine device ( IUD ) , birth control pill , birth control implant , condom , sponge spermicide . 7 . Subjects minimum stem cell dose 2.0 x 10^6 cluster differentiation 34 ( CD34 ) + cells/kg collect . 8 . Ability provide write informed consent prior initiation studyrelated procedure , ability , opinion Principal Investigator , comply requirement study . 1 . Prior treatment history allogeneic HSCT medical reason , limited myeloma treatment . 2 . Prior treatment history one autologous HSCT highdose chemotherapy stem cell rescue medical reason , limited myeloma treatment . 3 . Prior treatment busulfan gemtuzumab ozogamicin reason . 4 . Presence ( 4 ; 14 ) p53 gene deletion determine fluorescence situ hybridization ( FISH ) screen process document ( 4 ; 14 ) p53 gene deletion obtain time active disease method . 5 . Systemic amyloidosis . 6 . Known allergy boron component bortezomib . 7 . Left ventricular ejection fraction ( LVEF ) &lt; 45 % measure either multigated acquisition scan ( MUGA ) echocardiogram ( ECHO ) perform within 75 day prior day busulfan test dose . If cyclophosphamide use stem cell harvest , ECHO MUGA must do prior enrollment confirm adequate cardiac function . 8 . Uncontrolled arrhythmia symptomatic cardiac disease time screen . 9 . Symptomatic pulmonary disease , base Forced Expiratory Volume 1 Second ( FEV1 ) , Forced Vital Capacity ( FVC ) Diffusing Capacity Lung Carbon Monoxide ( DLCO ) &lt; 50 % predict ( correct hemoglobin ) measure within 75 day prior day busulfan test dose . 10 . Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) ≥ 3 x upper limit normal ( ULN ) , 11 . History elevate total serum bilirubin &gt; 2 mg/dL cause previous chemotherapy point , total bilirubin &gt; 2.0 mg/dL time screen exception Gilbert 's disease . 12 . Hepatic synthetic dysfunction evident International Normalized Ratio ( INR ) ≥ 2.0 time screen . 13 . Any previous history fulminant liver failure , cirrhosis , alcoholic hepatitis , esophageal varix , hepatic encephalopathy , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , symptomatic biliary disease . 14 . Prior total body irradiation therapy radiation therapy directly apply liver . 15 . Known history current hepatitis B , hepatitis C , HIV , uncontrolled active infection kind time test dose . If serology antibody study positive , quantitative polymerase chain reaction ( PCR ) must complete confirm lack active infection . 16 . Serum creatinine &gt; 2.0 mg/dL time Screening . 17 . ≥ Grade 1 neuropathy pain , &gt; Grade 2 neuropathy without pain ( subject neuropathy cause previous regimen recover ≤ Grade 2 stable without pain may include ) . 18 . Women pregnant lactating . 19 . Current history drug and/or alcohol abuse . 20 . Use investigational therapy within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Bone marrow transplant</keyword>
	<keyword>Stem cell transplant</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Bortezomib</keyword>
</DOC>